The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

media

posted on 01.12.2020, 10:21 by Jerome Goldschmidt, Vladimir Hanes

Article full text

The above video and summary slide represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40487-020-00133-1

Usage metrics

Read the peer-reviewed publication

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

Oncology and Therapy

Keywords

ABP 215 Cervical cancer Colorectal cancer Epithelial ovarian Fallopian tube Glioblastoma Non-small cell lung cancer Primary peritoneal cancer Renal cell carcinoma

Licence

CC BY-NC 4.0

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports